Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

NCT01644877 is registered in ClinicalTrials.gov with Ansun Biopharma, Inc. as lead sponsor.

NCT NCT01644877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01644877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
Lead sponsor
Ansun Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
December 15, 2016
Enrollment
111 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

parainfluenza